Tris Pharma - South Brunswick Township, NJ
posted about 2 months ago
Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. that focuses on the development and commercialization of innovative medicines addressing unmet patient needs. With over 150 US and International patents, the company has marketed several branded and generic products in the U.S. and has a robust pipeline of innovative products spanning neuroscience and other therapeutic categories. The Revenue/Gross-to-Net Analyst - Brand plays a crucial role in providing operational support to the Finance team by leading the Brand Gross to Net function. This position involves assisting with timely and accurate maintenance and completion of financial closing activities in compliance with Generally Accepted Accounting Principles (GAAP). The qualified candidate will be responsible for sales reporting, gross to net analysis, and other general finance activities, including journal entries and account reconciliations, to support department operations and analysis. The essential functions of this role include leading the Brand gross-to-net financial close process, performing analysis of sales, returns, Medicaid data, Managed Care data, chargebacks, wholesaler inventories & fees, and voucher programs to ensure accuracy and appropriate reserves. The analyst will prepare and post month-end accrual entries, collaborate with commercial operations and other key stakeholders on various aspects of Brand Revenue reporting, and prepare monthly and quarterly Brand Revenue schedules to facilitate Financial Reporting. Additionally, the analyst will reconcile Brand Fee for Service invoices, coordinate approval and credit memo issuance, assist with mandatory government reporting, and work with external auditors to provide required schedules and support for audits. The role also involves performing ad hoc reporting and analysis as needed, supporting the improvement of internal controls, and maintaining the Brand GTN accrual table per contract terms and estimated GTN rates.